 |
2 Diseases |  |
1 Trial |
|
1 Trial |  |
6 News |  |
- || staccato fentanyl (AZ-003) / Ferrer International
Clinical, Journal: Efficacy and safety of fentanyl inhalant for the treatment of breakthrough cancer pain: a multicenter, randomized, double-blind, placebo-controlled trial. (Pubmed Central) - Sep 8, 2024
P1/2, P2
Treatment with fentanyl inhalant was shown to be a promising therapeutic option for BTcP, with significant pain relief starting very soon after dosing. Confirmation of effectiveness requires a larger phase III trial.
- staccato fentanyl (AZ-003) / Ferrer International
Inhaled fentanyl aerosol through a drug-device combination for breakthrough cancer pain: A multicenter, randomized, double-blind, placebo-controlled trial. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_4859;
P2
It provides a non-invasive route for systemic drug delivery and can be self-administered or given by family caregivers as personalized and regular pain management. Clinical trial information: NCT05531422.
- |||| staccato fentanyl (AZ-003) / Ferrer International
New P2 trial: Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With BTcP (clinicaltrials.gov) - Sep 8, 2022
P2, N=60, Not yet recruiting, Sponsor: Lee's Pharmaceutical Limited
- |||| staccato fentanyl (AZ-003) / Ferrer International
New P1/2 trial: Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With Breakthrough Cancer Pain (clinicaltrials.gov) - Jan 18, 2021
P1/2, N=96, Not yet recruiting, Sponsor: Lee's Pharmaceutical Limited
- || staccato fentanyl (AZ-003) / Ferrer International
Review, Journal: 14-3-3σ and Its Modulators in Cancer. (Pubmed Central) - Dec 9, 2020
Additionally, this review will also include the discussions of the recent efforts by a different group of researchers for understanding the binding mechanisms of existing 14-3-3σ PPI modulators. The strategies and state-of-the-art techniques applied by various group of researchers in the discovery of a different chemical class of 14-3-3σ modulators for cancer are also briefly discussed in this review, which can be used as a guide in the development of new 14-3-3σ modulators in the near future.